Randomized controlled trial (RCT) of symptom screening with targeted early palliative care (STEP) versus usual care in patients with advanced cancer.

Authors

null

Camilla Zimmermann

Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

Camilla Zimmermann , Ashley Pope , Breffni Hannon , Monika K. Krzyzanowska , Gary Rodin , Madeline Li , Doris Howell , Jennifer J. Knox , Natasha B. Leighl , Srikala S. Sridhar , Amit M. Oza , Rebecca M. Prince , Stephanie Lheureux , Aaron Richard Hansen , Neesha C. Dhani , Geoffrey Liu , Philippe L. Bedard , Eric Xueyu Chen , Nadia Swami , Lisa W Le

Organizations

Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada, Princess Margaret Cancer Centre, Toronto, ON, Canada, Princess Margaret Hospital, Toronto, Ontario, Canada, Palliative Care and Psychosocial Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada, Wallace McCain Center for Pancreatic Cancer, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada, Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, University Health Network, Toronto, ON, Canada, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada

Research Funding

Other Government Agency

Background: To direct limited specialized palliative care resources to patients in greatest need, we developed STEP (Symptom screening with Targeted Early Palliative care). STEP entails symptom screening (ESAS-r) at each oncology clinic visit and triggered alerts (for moderate-high physical and psychological symptoms) to a nurse who calls the patient to offer a palliative care clinic (PCC) visit. We conducted a phase III RCT to assess the impact of STEP versus usual care on quality of life and other patient-reported outcomes (PROs). Methods: Adults with advanced cancer were recruited from medical oncology clinics at the Princess Margaret Cancer Centre, Toronto, Canada. Consenting patients with oncologist-assessed ECOG 0-2 and estimated survival of 6-36 months were enrolled and block randomized (stratified by tumour site and symptom severity) to STEP or usual care. Participants completed measures of quality of life (FACT-G7), depression (PHQ-9), symptom control (ESASr-CS), and satisfaction with care (FAMCARE-P16) at baseline, 2, 4 and 6 months. The primary outcome was FACT-G7 at 6 months, with a planned sample size of 261/arm. Results: From 8/2019 to 3/2020, 69 patients were enrolled: 33 randomized to STEP and 36 to usual care. The trial was then halted permanently due to the COVID-19 pandemic, owing to substantial changes to elements of STEP (shift to virtual symptom screening and palliative care) and usual care (shift to virtual oncology care). Median age was 64 years (range 25-87) and 62% (43/69) were women; study arms were balanced at baseline except gender, with more women randomized to STEP. Within the STEP arm, 20 (61%) participants triggered a nurse’s call to offer a PCC visit, of whom 13 attended the clinic at least once. All outcomes tended to be better in the STEP arm compared to usual care, particularly depression and satisfaction with care at 6 months; however, results were not statistically significant (Table). Conclusions: STEP holds promise for improving quality of life and other PROs in patients with advanced cancer and effectively directing early palliative care towards those who need it most. In response to the pandemic, an online version of STEP has been developed and a further trial is in progress. Clinical trial information: NCT03987906.

Patient-reported outcomes at baseline and 6 months.

Measure
STEP
Usual Care
Difference between STEP and Usual Care (95% CI)
p1
p2
n
Mean ±SD
n
Mean ±SD
FACT-G7: baseline
33
18.5 ± 5.1
36
19.7 ± 4.3
6 mo.
21
18.9 ± 4.8
24
17.4 ± 6.4
1.46 (-2.0 to 4.9)
0.30
0.55
ESAS-r-CS TDS: baseline
33
20.7 ± 16.9
36
20.0 ± 13.1
6 mo.
21
22.0 ± 15.6
24
28.1 ± 16.8
-6.2 (-15.9 to 3.6)
0.23
0.39
FAMCARE-P16: baseline
33
67.3 ± 12.5
36
70.3 ± 12.2
6 mo.
21
70.2 ± 8.9
25
64.6 ± 13.7
5.6 (-1.4 to 12.6)
0.08
0.21
PHQ-9: baseline
33
4.4 ± 4.3
36
4.9 ± 3.6
6 mo.
21
4.4 ± 4.0
25
7.4 ± 4.9
-3.0 (-5.7 to -0.3)
0.08
0.19

1adjusting for baseline score; 2adjusting for baseline score, symptoms, tumour site, and gender

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Palliative Care and Symptom Management

Clinical Trial Registration Number

NCT03987906

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr e24084)

DOI

10.1200/JCO.2022.40.16_suppl.e24084

Abstract #

e24084

Abstract Disclosures